Trade

with

Horizon Pharma PLC
(NASDAQ: HZNP)
AdChoices
11.87
-0.37
-3.02%
After Hours :
11.87
0.00
0.00%

Open

12.22

Previous Close

12.24

Volume (Avg)

1.05M (2.10M)

Day's Range

11.67-12.38

52Wk Range

3.70-18.30

Market Cap.

915.18M

Dividend Rate ( Yield )

-

Beta

2.59

Shares Outstanding

74.77M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 74.02M

    • Net Income

    • -149.00M

    • Market Cap.

    • 915.18M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -198.87

    • PEG (Price/Earnings Growth) Ratio

    • 0.67

    • Beta

    • 2.59

    • Forward P/E

    • 13.02

    • Price/Sales

    • 4.80

    • Price/Book Value

    • 11.35

    • Price/Cash flow

    • -169.49

      • EBITDA

      • -33.54M

      • Return on Capital %

      • -140.66

      • Return on Equity %

      • -453.57

      • Return on Assets %

      • -140.66

      • Book Value/Share

      • 1.08

      • Shares Outstanding

      • 74.77M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 24.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 493.50

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 76.25

            • 64.72

            • Pre-Tax Margin

            • -198.93

            • 13.77

            • Net Profit Margin

            • -198.87

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 0.97

              • 1.52

              • Quick Ratio

              • 0.88

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 4.07

              • 1.91

              • Book Value/Share

              • 1.08

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.30

                • 63.69

                • P/E Ratio 5-Year High

                • -3.61

                • 237.47

                • P/E Ratio 5-Year Low

                • -0.39

                • 19.71

                • Price/Sales Ratio

                • 4.58

                • 3.57

                • Price/Book Value

                • 10.81

                • 3.35

                • Price/Cash Flow Ratio

                • -169.49

                • 21.41

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -453.57

                        (-)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -140.66

                        (-78.20)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -218.36

                        (-)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • 5.46

                      • 1.80

                      • Asset Turnover

                      • 0.71

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -42.85M
                      Operating Margin
                      -57.90
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -169.49
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      92.70%

                      Mutual Fund Ownership

                      32.50%

                      Float

                      88.58%

                      5% / Insider Ownership

                      0.67%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        5,259,946

                      • 0.00

                      • 7.03

                      • SPDR® S&P Pharmaceuticals ETF

                      •  

                        2,709,427

                      • 0.00

                      • 3.51

                      • iShares Nasdaq Biotechnology

                      •  

                        1,406,695

                      • -0.69

                      • 1.82

                      • iShares Russell 2000 (AU)

                      •  

                        1,009,816

                      • -1.02

                      • 1.31

                      • Vanguard Total Stock Mkt Idx

                      •  

                        881,388

                      • 0.00

                      • 1.18

                      • Fidelity Advisor® Biotechnology Fund

                      •  

                        811,450

                      • 0.00

                      • 1.09

                      • T. Rowe Price Health Sciences Fund

                      •  

                        684,000

                      • -0.34

                      • 0.92

                      • Vanguard Explorer Fund

                      •  

                        622,225

                      • -17.64

                      • 0.84

                      • Pru Ret Small Cap Growth/TimesSquare SP

                      •  

                        583,000

                      • 34.49

                      • 0.78

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vidara Therapeutics Holdings LLC

                      •  

                        31,350,000

                      • 0.00%

                      • 41.93

                      • Essex Woodlands Health Ventures

                      •  

                        5,815,940

                      • 0.00%

                      • 7.57

                      • Essex Woodlands Health Ventures, Inc

                      •  

                        5,815,940

                      • +14.83%

                      • 8.14

                      • Fidelity Management and Research Company

                      •  

                        4,408,313

                      • -0.51%

                      • 5.93

                      • Broadfin Capital, LLC

                      •  

                        4,353,214

                      • +1.11%

                      • 5.86

                      • Atlas Venture Inc

                      •  

                        3,895,404

                      • +5.62%

                      • 5.45

                      • State Street Corp

                      •  

                        3,070,378

                      • +5.44%

                      • 4.13

                      • Quaker BioVentures Capital II, LLC

                      •  

                        2,857,088

                      • -18.74%

                      • 3.82

                      • Sutter Hill Ventures

                      •  

                        2,837,826

                      • +35.36%

                      • 4.29

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Horizon Pharma PLC was incorporated on March 23, 2010. The Company is a specialty pharmaceutical company commercializing DUEXIS, VIMOVO and RAYOS/LODOTRA, each of which targets unmet therapeutic needs in arthritis, pain and inflammat...moreory diseases. DUEXIS is a proprietary single tablet formulation containing a fixed-dose combination of ibuprofen, one of the widely prescribed NSAIDs, and famotidine, a well-established GI agent used to treat dyspepsia, gastroesophageal reflux disease, or GERD, and active ulcers, in one pill. Ibuprofen has proven anti-inflammatory and analgesic properties and famotidine reduces the stomach acid secretion that can cause upper GI ulcers. VIMOVO is a proprietary fixed-dose multi-layer delayed-release tablet combining an enteric-coated naproxen, an NSAID, core and an immedia...morete-release esomeprazole, a PPI, layer surrounding the core. Naproxen has proven anti-inflammatory and analgesic properties and esomeprazole reduces the stomach acid secretions that can cause upper GI ulcers. RAYOS, known as LODOTRA outside the United States, is a proprietary delayed-release formulation of low-dose prednisone for the treatment of moderate to severe, active RA in adults particularly when accompanied by morning stiffness. DUEXIS and VIMOVO compete with other branded NSAIDs, including Celebrex, marketed by Pfizer Inc. RAYOS/LODOTRA competes in Europe and in the United States with a number of products on the market to treat RA, including corticosteroids, such as prednisone, traditional DMARDs, such as methotrexate and biologic agents, such as HUMIRA and Enbrel.lessless

                      Key People

                      Mr. Timothy P. Walbert

                      CEO/CEO, Subsidiary/Chairman of the Board/Director/President/President, Subsidiary

                      Mr. Paul W. Hoelscher

                      Executive VP/CFO/Chief Accounting Officer

                      Jeffrey W. Sherman,M.D.

                      Chief Medical Officer/Executive VP, Divisional/Executive VP, Subsidiary/Other Executive Officer

                      Robert Carey

                      Executive VP/Other Executive Officer

                      Mr. Barry Moze

                      Executive VP, Divisional

                      • Horizon Pharma PLC

                      • Adelaide Chambers

                      • Dublin 8, 60015

                      • USA.Map

                      • Phone: +353 16498521

                      • Fax: -

                      • horizonpharma.com

                      Incorporated

                      2010

                      Employees

                      436

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: